UroGen Pharma Announces Positive Clinical Results for ZUSDURI™ in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
Reuters
Oct 02
<a href="https://laohu8.com/S/URGN">UroGen</a> Pharma Announces Positive Clinical Results for ZUSDURI™ in Recurrent Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd. has announced the publication of a comprehensive clinical review of ZUSDURI™ (mitomycin) for intravesical solution, the first and only FDA-approved medication for adults with recurrent, low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The review, published in the peer-reviewed journal *Reviews in Urology™*, summarizes data from three late-phase clinical trials-OPTIMA II, ATLAS, and ENVISION-evaluating the safety and efficacy of ZUSDURI in this patient population. Results from these studies have already been presented and indicate complete response rates between 64.8% and 79.6% at three months. ZUSDURI is administered as a non-surgical, outpatient treatment and is reported to have a safety profile manageable in routine urologic practice.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9538923-en) on October 02, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.